SCHEMBL4017654

SCHEMBL4017654

CC(=O)Oc1cccc(C(=O)NC2CCN(c3ncnc4cc(Cl)ccc34)CC2)c1.NC1CCN(c2ncnc3cc(Cl)ccc23)CC1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 3/20 0.55
SUV39H1 O43463 2/20 0.55
PRMT1 Q99873 2/20 0.55
PAK1 Q13153 10/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
STK4 Q13043 1/20 0.43
STK3 Q13188 1/20 0.43
LRRK2 Q5S007 1/20 0.43
CCNE1 P24864 2/20 0.42
CDK2 P24941 2/20 0.42
MAP3K6 O95382 1/20 0.41
MAP3K5 Q99683 1/20 0.41
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
GRM5 P41594 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021963 0.96 CYP1A2 (0.49) SMYD3SUV39H1PRMT1PAK1CYP1A2
SCHEMBL4017882 0.88 CLK1 (0.48) CCNE1CDK2
SCHEMBL4017646 0.88 GRM5 (0.53) SMYD3SUV39H1PRMT1PAK1CYP1A2
SCHEMBL4024378 0.85 CYP1A2 (0.57) SMYD3SUV39H1PRMT1PAK1CYP1A2
SCHEMBL4016242 0.84 CCNE1 (0.51) SMYD3SUV39H1PRMT1PAK1CYP1A2
SCHEMBL4024538 0.83 CLK1 (0.52) CCNE1CDK2
SCHEMBL4023998 0.83 CYP1A2 (0.53) SMYD3SUV39H1PRMT1PAK1CYP1A2
SCHEMBL4582190 0.83 CCNE1 (0.50) PAK1CCNE1CDK2GRM5
SCHEMBL4022823 0.81 CYP1A2 (0.53) SMYD3SUV39H1PRMT1PAK1CYP1A2
SCHEMBL4021891 0.81 SUV39H1 (0.52) SMYD3SUV39H1PRMT1PAK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066654-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS Bayer Schering Pharma AG (DE) 2009-06-10 EP claimed
WO-2008028691-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-13 WO claimed